The U.S. drug testing market size was estimated at USD 2.62 billion in 2025, projected to reach USD 4.13 billion by 2033, expanding at a CAGR of 5.89% from 2026 to 2033. The growth of the market is driven by rising prevalence of substance abuse, stringent regulations requiring drug & alcohol testing, and growing government efforts to curb substance abuse in the U.S.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 national survey on drug use and health, about 73.6 million Americans aged twelve or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine.
Furthermore, growing emphasis on workplace safety and compliance across industries is also supporting the expansion of the U.S. drug testing market. Many employer liability issues are driving the adoption of pre-employment, random, and post-incident drug testing programs, supporting market demand. The expansion of drug testing across workplaces and healthcare settings further contributes to growth. Moreover, the U.S. government actively promotes national campaigns to raise awareness about the dangers of substance abuse. Programs such as “National Drug & Alcohol Facts Week” and the DEA’s educational outreach provide schools, communities, and workplaces with resources to prevent drug misuse.
The increasing prevalence of substance abuse in the U.S. has significantly raised the demand for drug testing solutions. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing market.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 national survey on drug use and health, about 73.6 million Americans aged twelve or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine.
Furthermore, growing emphasis on workplace safety and compliance across industries is also supporting the expansion of the U.S. drug testing market. Many employer liability issues are driving the adoption of pre-employment, random, and post-incident drug testing programs, supporting market demand. The expansion of drug testing across workplaces and healthcare settings further contributes to growth. Moreover, the U.S. government actively promotes national campaigns to raise awareness about the dangers of substance abuse. Programs such as “National Drug & Alcohol Facts Week” and the DEA’s educational outreach provide schools, communities, and workplaces with resources to prevent drug misuse.
The increasing prevalence of substance abuse in the U.S. has significantly raised the demand for drug testing solutions. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing market.
U.S. Drug Testing Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the U.S. drug testing market report on the basis of test, application, and end use.Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments
- Rapid Testing Devices
- Services
Sample Type Outlook (Revenue, USD Million, 2021-2033)
- Urine Samples
- Oral Fluid Samples
- Hair Samples
- Other Samples
Drug Type Outlook (Revenue, USD Million, 2021-2033)
- Alcohol
- Cannabis/Marijuana
- Cocaine
- Opioids
- Amphetamine & Methamphetamine
- LSD
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Drug Testing Laboratories
- Workplaces
- Hospitals
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Drug Testing Market Variables, Trends & Scope
Chapter 4. U.S. Drug Testing Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Drug Testing Market: Sample Type Estimates & Trend Analysis
Chapter 6. U.S. Drug Testing Market: Drug Type Estimates & Trend Analysis
Chapter 7. U.S. Drug Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Quest Diagnostics Incorporated
- Abbott
- Laboratory Corporation of America Holdings (LabCorp)
- Thermo Fisher Scientific, Inc.
- OraSure Technologies, Inc
- Psychemedics Corporation
- Omega Laboratories, Inc
- Premier Biotech, Inc
- Alfa Scientific Designs, Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.62 Billion |
| Forecasted Market Value ( USD | $ 4.13 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
